Share this article
Share this article
HAMILTON, Ontario and BOSTON, Feb. 11, 2021 /PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Philina Lee, Ph.D., as a member of the Company s Board of Directors. Dr. Lee, who currently serves as senior vice president, head of portfolio strategy at Blueprint Medicines Corporation, brings to the board 15 years of experience in the biopharmaceutical industry. She previously was head of U.S. marketing for Algeta, developer of the first marketed alpha-emitting radiopharmaceutical. Philina s depth of both precision oncology and radiopharmaceutical industry experience will be valuable to us as we continue to progress our Targeted Alpha Therapies (TAT) platform and grow our pipeline of clinical candidates, said Fusion Chief Executive Officer John Valliant, Ph.D. Additionally, her le
/PRNewswire/ Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, systemic mastocytosis, and.
E-Mail
Like weeds sprouting from cracks in the pavement, cancer often forms in sites of tissue damage. That damage could be an infection, a physical wound, or some type of inflammation. Common examples include stomach cancer caused by H. pylori infection, Barrett s esophagus caused by acid reflux, and even smoking-induced lung cancer.
Exactly how tissue damage colludes with genetic changes to promote cancer isn t fully understood. Most of what scientists know about cancer concerns advanced stages of the disease. That s especially true for cancers such as pancreatic cancer that are usually diagnosed very late.
Researchers in Scott Lowe s lab at the Sloan Kettering Institute are now trying to zero in on the earliest stages of pancreatic cancer development.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
Blueprint Medicines Announces R&D Leadership Transitions Becker Hewes, M.D., promoted to Chief Medical Officer Andy Boral, M.D., Ph.D., to transition from Chief Medical Officer to Executive Vice President, Clinical Development Marion Dorsch, Ph.D., Chief Scientific Officer, to depart the company
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., Jan. 11, 2021 /PRNewswire/ Blueprint Medicines Corporation (NASDAQ: BPMC) today announced leadership transitions for the company s research and development organization. Effective as of January 11, 2021, Becker Hewes, M.D., currently Senior Vice President, Clinical Development, will succeed Andy Boral, M.D., Ph.D., as Chief Medical Officer, and Dr. Boral will transition to a new role as Executive Vice President, Clinical Development. With his promotion, Dr. Hewes will be responsible for clinical development, clinical operations, pharmacovigilance, translational medicine and biostatistics. In his new